Literature DB >> 16461312

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.

Martin Kaiser1, Ivana Zavrski, Jan Sterz, Christian Jakob, Claudia Fleissner, Peter-Michael Kloetzel, Orhan Sezer, Ulrike Heider.   

Abstract

The aim of this study was to evaluate the effects of valproic acid (VPA), as a histone deacetylase inhibitor, on myeloma cell lines and on sorted human bone marrow multiple myeloma cells. VPA induced accumulation of acetylated histones, potently inhibited proliferation in a dose-dependent manner and induced apoptosis in all myeloma cell lines tested as well as in sorted primary multiple myeloma cells. Cell cycle analysis indicated an arrest in G0/1 phase in response to VPA. Accumulation of p21 and reduced levels of cyclin D1 were detected. The production of vascular endothelial growth factor was significantly inhibited by VPA. These results provide the framework for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461312

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  29 in total

1.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

2.  Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo.

Authors:  Jyoti Joshi Mundra; Alexandra Terskiy; Richard D Howells
Journal:  J Pharmacol Exp Ther       Date:  2012-04-26       Impact factor: 4.030

3.  HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.

Authors:  Choon-Kee Lee; Shuiliang Wang; Xiaoping Huang; John Ryder; Bolin Liu
Journal:  Cancer Lett       Date:  2010-05-05       Impact factor: 8.679

4.  Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.

Authors:  Bevin Zimmerman; Aaron Sargeant; Kristina Landes; Soledad A Fernandez; Ching-Shih Chen; Michael D Lairmore
Journal:  Leuk Res       Date:  2011-07-29       Impact factor: 3.156

5.  The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

Authors:  Shuhong Zhang; Attaya Suvannasankha; Colin D Crean; Valerie L White; Ching-Shih Chen; Sherif S Farag
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

6.  Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.

Authors:  Ken-Ichi Kitazoe; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Takeshi Harada; Ayako Nakano; Kyoko Takeuchi; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

7.  Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.

Authors:  David Yu Greenblatt; Max A Cayo; Joel T Adler; Li Ning; Megan R Haymart; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg       Date:  2008-06       Impact factor: 12.969

8.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23

9.  Impairment of liver regeneration by the histone deacetylase inhibitor valproic acid in mice.

Authors:  Qi Ke; Rui-na Yang; Feng Ye; Yu-jia Wang; Qiong Wu; Li Li; Hong Bu
Journal:  J Zhejiang Univ Sci B       Date:  2012-09       Impact factor: 3.066

10.  The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.

Authors:  Malin Ageberg; Karin Rydström; Thomas Relander; Kristina Drott
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.